A Prospective Phase 2 Clinical Trial to Assess the Efficacy and Safety of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis Patients
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Xiamen Amoytop Biotech
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 20 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
- 24 Mar 2015 Planned End Date changed from 1 Dec 2017 to 1 Jun 2016 as reported by ClinicalTrials.gov record.